Characteristics and impact of drug detailing for gabapentin

PLoS Medicine

Volumn 4, Issue 4, 2007, Pages 743-751

  Steinman, Michael A ^a,b   Harper, G Michael ^a,b   Chren, Mary Margaret ^a,c   Landefeld, C Seth ^a,b   Bero, Lisa A ^b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; 4 AMINOBUTYRIC ACID; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG INDICATION; DRUG INFORMATION; DRUG MARKETING; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIVARIATE ANALYSIS; OFF LABEL DRUG USE; PHYSICIAN; PRESCRIPTION; RECORDING; SEIZURE; UNITED STATES; DRUG INDUSTRY; ECONOMICS; MARKETING; METHODOLOGY;

AMINES; CYCLOHEXANECARBOXYLIC ACIDS; DRUG INDUSTRY; GAMMA-AMINOBUTYRIC ACID; HUMANS; MARKETING; PHYSICIANS;

EID: 34247486946     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040134     Document Type: Article

References (65)

1. Manchanda P, Honka E (2005) The effects and role of direct-to-physician marketing in the pharmaceutical industry: An integrative review. Yale J Health Policy Law Ethics 5: 785-822.
2. Angell M (2004) The truth about the drug companies: How they deceive us and what to do about it. 1st Ed. New York: Random House. 336 p.
3. Kassirer J (2005) On the take: How America's complicity with big business can endanger your health. New York: Oxford University Press. 272 p.
4. Avorn J (2004) Powerful medicines: The benefits, risks, and costs of prescription drugs. 1st Ed. New York: Knopf. 480 p.
5. Ziegler MG, Lew P, Singer BC (1995) The accuracy of drug information from pharmaceutical sales representatives. JAMA 273: 1296-1298.
6. Hemminki E (1977) Content analysis of drug-detailing by pharmaceutical representatives. Med Educ 11: 210-215.
7. Stryer D, Bero LA (1996) Characteristics of materials distributed by drug companies. An evaluation of appropriateness. J Gen Intern Med 11: 575-583.
8. Chren MM, Landefeld CS, Murray TH (1989) Doctors, drug companies, and gifts. Jama 262: 3448-3451.
9. Dana J, Loewenstein G (2003) A social science perspective on gifts to physicians from industry. JAMA 290: 252-255.
10. Waxman HA (2005 May 5) Memorandum to Democratic Members of House Government Reform Committee: The Marketing of Vioxx to Physicians. Available: http://www.democrats.reform.house.gov/documents/20050505114932-41272.pdf. Accessed 5 May 2005.
11. Tiner R (1999) Reasons for not seeing drug representatives. They should be seen because they are a good resource. BMJ 319: 1002.
12. Thomson AN, Craig BJ, Barham PM (1994) Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract 44: 220-223.
13. Benbow AG (1999) Reasons for not seeing drug representatives. Drug representatives have much to offer. BMJ 319: 1003.
14. Lexchin J (1993) Interactions between physicians and the pharmaceutical industry: What does the literature say? CMAJ 149: 1401-1407.
15. Wazana A (2000) Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 283: 373-380.
16. Steinman MA, Shlipak MG, McPhee SJ (2001) Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 110: 551-557.
17. Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG (2004) Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 42: 1176-1185.
18. Mizik N, Jacobson R (2003) Are physicians "easy marks"?: Quantifying the effects of detailing and sampling on new prescriptions. ISBM Report 9-2003. University Park (Pennsylvania): Institute for the Study of Business Markets. Available: http://www.smeal.psu.edu/isbm/database/documents/ wp03/09-2003.pdf. Accessed 21 March 2007.
19. Schwartz TL, Kuhles DJ 2nd, Wade M, Masand PS (2001) Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits. Ann Clin Psychiatry 13: 159-162.
20. Manchanda P, Chintagunta PK (2004) Responsiveness of physician prescription behavior to salesforce effort: An individual level analysis. Marketing Lett 15: 129-145.
21. Parsons LJ, Abeele PV (1981) Analysis of sales call effectiveness. J Marketing Research 18: 107-113.
22. Roughead EE, Harvey KJ, Gilbert AL (1998) Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust N Z J Med 28: 306-310.
23. (2003) Performance of sales representatives in France: Still bad. Prescrire International 12: 153-154.
24. Shaughnessy AF, Slawson DC, Bennett JH (1995) Teaching information mastery: Evaluating information provided by pharmaceutical representatives. Fam Med 27: 581-585.
25. Brotzman GL, Mark DH (1993) The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities. J Gen Intern Med 8: 130-134.
26. McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, et al. (1990) Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA 264: 1693-1697.
27. Hodges B (1995) Interactions with the pharmaceutical industry: Experiences and attitudes of psychiatry residents, interns and clerks. CMAJ 153: 553-559.
28. Monaghan MS, Galt KA, Turner PD, Houghton BL, Rich EC, et al. (2003) Student understanding of the relationship between the health professions and the pharmaceutical industry. Teach Learn Med 15: 14-20.
29. US Department of Justice (2004 May 13) Warner-Lambert to pay $430 million to resolve criminal & civil health care liability relating to off-label promotion. Available: http://www.usdoj.gov/opa/pr/2004/May/04_civ_322. htm. Accessed 3 February 2005.
30. Steinman MA, Bero LA, Chren MM, Landefeld CS (2006) The promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145: 284-293.
31. US District Court for the District of Massachusetts (2003 May 15) Affidavit of Debra Farese with Exhibits A-E in United States of America ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company. Civil Action No. 96-11651-PBS. Available: http://dida.library.ucsf.edu/ pdf/qha00a10. Accessed 21 March 2007.
32. US District Court for the District of Massachusetts (2003 February 19) Exhibit 146 to the Affidavit of Thomas M. Greene in Support of Relator's Opposition to Defendant's Motion for Summary Judgment [Deposition of Debra Farese], in United States of America ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company. pp. 10,11, 25-32, 34, 37-48, 76-84, 87, 93-97. Civil Action No. 96-11651-PBS. Available: http://dida.library.ucsf.edu/pdf/eza00a10. Accessed 21 March 2007.
33. Sergeant MD, Hodgetts PG, Godwin M, Walker DM, McHenry P (1996) Interactions with the pharmaceutical industry: A survey of family medicine residents in Ontario. CMAJ 155: 1243-1248.
34. Caudill TS, Johnson MS, Rich EC, McKinney WP (1996) Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 5: 201-206.
35. Lurie N, Rich EC, Simpson DE, Meyer J, Schiedemayer DL, et al. (1990) Pharmaceutical representatives in academic medical centers: Interaction with faculty and housestaff. J Gen Intern Med 5: 240-243.
36. Bower AD, Burkett GL (1987) Family physicians and generic drugs: A study of recognition, information sources, prescribing attitudes, and practices. J Fam Pract 24: 612-616.
37. Peay MY, Peay ER (1988) The role of commercial sources in the adoption of a new drug. Soc Sci Med 26: 1183-1189.
38. Anadaleeb SS, Tallman RF (1996) Relationships of physicians with pharmaceutical sales representatives and pharmaceutical companies: An exploratory study. Health Mark Q 13: 79-89.
39. Peay MY, Peay ER (1990) Patterns of preference for information sources in the adoption of new drugs by specialists. Soc Sci Med 31: 467-476.
40. Hayes TM, Allery LA, Harding KG, Owen PA (1990) Continuing education for general practice and the role of the pharmaceutical industry. Br J Gen Pract 40: 510-512.
41. Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, et al. (2002) Third generation anticonvulsants in bipolar disorder: A review of efficacy and summary of clinical recommendations. J Clin Psychiatry 63: 275-283.
42. Chronicle E, Mulleners W (2004) Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev: CD003226.
43. Wiffen PJ, McQuay HJ, Edwards JE, Moore RA (2005) Gabapentin for acute and chronic pain. Cochrane Database Syst Rev: CD005452.
44. Steinman MA, Landefeld CS, Chren MM (2003) Expert consultant's report: United States ex rel. Franklin vs. Pfizer, Inc et al. Available at: http://dida.library.ucsf.edu/pdf/mha00a10. Accessed 12 January 2007.
45. Roughead EE, Gilbert AL, Harvey KJ (1998) Self-regulatory codes of conduct: Are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners? Int J Health Serv 28: 269-279.
46. Lexchin J (1997) What information do physicians receive from pharmaceutical representatives? Can Fam Physician 43: 941-945.
47. Shaughnessy AF, Slawson DC, Bennett JH (1994) Separating the wheat from the chaff: Identifying fallacies in pharmaceutical promotion. J Gen Intern Med 9: 563-568.
48. Molloy W, Strang D, Guyatt G, Lexchin J, Bedard M, et al. (2002) Assessing the quality of drug detailing. J Clin Epidemiol 55: 825-832.
49. Hovland CI, Weiss W (1951) The influence of source credibility on communication effectiveness. Public Opin Q 15: 635-650.
50. Calfee JE, Ringold DJ (1994) The 70% majority: Enduring consumer beliefs about advertising. J Public Policy Mark 13: 228-238.
51. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, et al. (1998) Closing the gap between research and practice: An overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 317: 465-468.
52. Avorn J, Soumerai SB (1983) Improving drug-therapy decisions through educational outreach. A randomized controlled trial of academically based "detailing." N Engl J Med 308: 1457-1463.
53. Soumerai SB, Avorn J (1990) Principles of educational outreach ("academic detailing") to improve clinical decision making. JAMA 263: 549-556.
54. Figueiras A, Sastre I, Tato F, Rodriguez C, Lado E, et al. (2001) One-to-one versus group sessions to improve prescription in primary care: A pragmatic randomized controlled trial. Med Care 39: 158-167.
55. Landefeld SM, Cheung AV (2004) Corporate governance: Improving board decisionmaking in post-Sarbanes-Oxley. Insights 18: 9-14.
56. van Eijk ME, Avorn J, Porsius AJ, de Boer A (2001) Reducing prescribing of highly anticholinergic antidepressants for elderly people: Randomised trial of group versus individual academic detailing. BMJ 322: 654-657.
57. Simon SR, Majumdar SR, Prosser LA, Salem-Schatz S, Warner C, et al. (2005) Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: A cluster-randomized controlled trial. Am J Med 118: 521-528.
58. Steinbrook R (2006) For sale: Physicians' prescribing data. N Engl J Med 354: 2745-2747.
59. Greene JA (2004) Attention to "details": Etiquette and the pharmaceutical salesman in postwar America. Soc Stud Sci 34: 271-292.
60. Zipkin DA, Steinman MA (2005) Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med 20: 777-786.
61. Madhavan S, Amonkar MM, Elliott D, Burke K, Gore P (1997) The gift relationship between pharmaceutical companies and physicians: An exploratory survey of physicians. J Clin Pharm Ther 22: 207-215.
62. Hopper JA, Speece MW, Musial JL (1997) Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives. J Gen Intern Med 12: 639-642.
63. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM (2002) Promotion of prescription drugs to consumers. N Engl J Med 346: 498-505.
64. Blumenthal D (2004) Doctors and drug companies. N Engl J Med 351: 1885-1890.
65. No Free Lunch (2007) Sources of drug info. Available: http://nofreelunch.org/sources_druginfo.htm. Accessed 27 April 2005.